Novelix Pharmaceuticals Ltd.
BSE: 536565
₹81.90
₹1.40
(1.74%)
As on 28-Aug-2026IST
Market cap
₹233 Cr
Revenue (TTM)
₹147 Cr
P/E Ratio
64.2
P/B Ratio
3.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹4 Cr
-
ROE
0.7 %
-
ROCE
1 %
-
Industry P/E
33.99
-
EV/EBITDA
50.7
-
Debt to Equity
0
-
Book Value
₹22.3
-
EPS
₹1.9
-
Face value
10
-
Shares outstanding
28,470,000
10 Years Aggregate
CFO
₹-12.55 Cr
EBITDA
₹-7.43 Cr
Net Profit
₹-6.41 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Novelix Pharmaceuticals
| 30.8 | 11.6 | 43.3 | 98.8 | 108.5 | 61.1 | 29.9 |
|
BSE Healthcare
| 18.8 | 2.8 | 8.7 | 17.1 | 23.1 | 14.8 | 12.4 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Novelix Pharmaceuticals
| 158.6 | 104.8 | 8.7 | 54.5 | 8.4 | 118.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Novelix Pharmaceuticals
|
81.9 | 233.2 | 146.9 | 3.6 | 3.0 | 10.1 | 64.2 | 3.7 |
| 7,106.5 | 17,765.6 | 2,432.1 | 169.6 | 8.7 | 20.8 | 104.7 | 19.6 | |
| 2,517.2 | 19,125.3 | 2,287.3 | 678.1 | 31.4 | 19.7 | 28.7 | 5.1 | |
| 2,079.5 | 12,740.0 | 1,479.1 | 198.6 | 18.6 | 30.3 | 64 | 15.8 | |
| 1,314.8 | 18,252.8 | 3,229.7 | 666.9 | 26.6 | 18.8 | 28.3 | 4.5 | |
| 2,408.9 | 38,730.8 | 4,147.8 | 709.5 | 22.3 | 19.1 | 54.6 | 9.3 | |
| 4,703.8 | 21,500.8 | 2,569.8 | 735.2 | 34.4 | 19.2 | 29.2 | 4.9 | |
| 5,670.5 | 9,412.3 | 1,432.9 | 356.9 | 30.8 | 58.2 | 26.4 | 15.3 | |
| 903.8 | 17,685.5 | 1,682.5 | 273.5 | 21.0 | 11.1 | 59.5 | 6.6 | |
| 1,019.9 | 9,406.7 | 5,004.4 | 635.3 | 14.5 | 19.8 | 15.3 | 2.9 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Novelix Pharmaceuticals
Other financial service activities, except insurance and pension funding activities
-
Incorporated
1994
-
Chairman
--
-
Managing Director
--
-
Headquarters
Hyderabad, Telangana
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Novelix Pharmaceuticals
What is the current share price of Novelix Pharmaceuticals Ltd Today?
The share price of Novelix Pharmaceuticals Ltd is ₹81.90 (BSE) as of 28-Aug-2026 IST. Novelix Pharmaceuticals Ltd has given a return of 108.54% in the last 3 years.
What is the current PB & PE ratio of Novelix Pharmaceuticals Ltd?
The P/E ratio of Novelix Pharmaceuticals Ltd is 64.23 times as on 28-Aug-2026, a 89 premium to its peers’ median range of 33.99 times.
The P/B ratio of Novelix Pharmaceuticals Ltd is 3.67 times as on 28-Aug-2026, a 27 discount to its peers’ median range of 5.06 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
313.43 |
1.51 |
2024 |
1,332.56 |
1.89 |
2023 |
0.00 |
1.01 |
2022 |
0.00 |
0.97 |
2021 |
0.00 |
0.80 |
What is the 52 Week High and Low of Novelix Pharmaceuticals Ltd?
The 52-week high and low of Novelix Pharmaceuticals Ltd are Rs 92.00 and Rs 38.00 as of 30-Aug-2026.
What is the market cap of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd has a market capitalisation of ₹ 233 Cr as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Novelix Pharmaceuticals Ltd?
Before investing in Novelix Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.